TMDXTransMedics Group, Inc.
Electromedical & Electrotherapeutic Apparatus
- Revenue
- $605M
- 37% YoY
- Operating margin
- 17.9%
- 111% YoY
- EBITDA
- $136M
- 137% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -2.2×
- −$296M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear101% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $31M | $93M | $242M | $442M | $605M | 37% |
| Operating income | −$39M | −$31M | −$29M | $37M | $109M | 190% |
| Net income | −$44M | −$36M | −$25M | $36M | $190M | 436% |
| Operating cash flow | −$29M | −$46M | −$13M | $49M | $193M | 295% |
| Capex | $4M | $12M | $152M | $130M | $59M | 54% |
| Stock-based comp | $7M | $10M | $20M | $33M | $37M | 11% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $109K · 1
- Open-market sells, 12 mo
- $178K · 1
- Net
- −$69K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $11M | $26M | 611 | 99 |
| FY2024 | $8M | $10M | 313 | 81 |
| FY2023 | $7M | $13M | 397 | 82 |
| FY2022 | $3M | $25M | 310 | 77 |
| FY2021 | $7M | $5M | 96 | 96 |